AstraZeneca’s bladder cancer combination cut death risk by 42%, but can it compete with an approved rival regimen?
AstraZeneca's VOLGA trial shows 42% lower death risk with IMFINZI and enfortumab vedotin. Can the regimen compete with approved bladder cancer therapy?